Cutler Group’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-25,100
Closed -$1K 5612
2021
Q2
$1K Sell
25,100
-13,200
-34% -$23.2K ﹤0.01% 5181
2021
Q1
$4K Buy
38,300
+15,600
+69% +$35.7K ﹤0.01% 4452
2020
Q4
$7K Sell
22,700
-26,600
-54% -$55.9K ﹤0.01% 3403
2020
Q3
$9K Buy
+49,300
New +$135K ﹤0.01% 3041

Other funds holding ADMA

Cutler Group's ADMA Position: Q1 2023 in Review

Cutler Group sold out of ADMA Biologics (ADMA) in Q1 2023, closing a stake of 2,000 shares — an estimated $7K sold.

Cutler Group first reported a position in ADMA in Q1 2019 and held it in 10 quarters. The position peaked at $87K in Q1 2021. 163 funds tracked by Wall St. Rank hold ADMA as of Q1 2023.

  • Cutler Group reported no remaining ADMA Biologics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 2,000 ADMA Biologics shares in Q1 2023, an estimated $7K.
  • Cutler Group first reported a position in ADMA Biologics in Q1 2019 and held it in 10 quarters.
  • Cutler Group's ADMA Biologics position peaked at $87K in Q1 2021.
  • 163 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.